AR086156A1 - Compuesto de amida y su uso medicinal - Google Patents
Compuesto de amida y su uso medicinalInfo
- Publication number
- AR086156A1 AR086156A1 ARP120101498A ARP120101498A AR086156A1 AR 086156 A1 AR086156 A1 AR 086156A1 AR P120101498 A ARP120101498 A AR P120101498A AR P120101498 A ARP120101498 A AR P120101498A AR 086156 A1 AR086156 A1 AR 086156A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- different substituents
- substituents selected
- alkyl group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composiciones farmacéuticas.Reivindicación 1: Un compuesto de la fórmula (1) caracterizado porque el resto de formulas (2) es seleccionado de las fórmulas (3) ó (4); Ra es (I) grupo alquilo C5-12 que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A o (II) grupo de formula (5) en donde Ya es (i) enlace simple o (ii) grupo alquileno C1-6; resto cíclico U es (i) grupo cicloalquilo C3-7 que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A, (ii) grupo cicloalquilo C5-11 espirocíclico que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A o (iii) grupo arilo C6-10 que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A; Rb es un grupo seleccionado de los siguientes (i) a (iii): (i) grupo alquilo C1-3 que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A, (ii) grupo alquenilo C2-3 que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A, (iii) grupo cicloalquilo C3-7 que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A; Rc es (i) átomo de hidrógeno o (ii) grupo alquilo C1-6; Yc es un grupo seleccionado de los siguientes (i) a (vii): (i) enlace simple, (ii) grupo alquileno C1-6 que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A, (iii) -NRC1-, en donde RC1 es átomo de hidrógeno o grupo alquilo C1-6, (iv) -O-, (v) grupo cicloalquileno C3-10 que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A, (vi) grupo arileno C6-10 que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A, (vii) grupo heteroaromático monocíclico que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A en donde el anillo heteroaromático monocíclico consiste en átomos de carbono y 1 a 4 heteroátomos iguales o diferentes seleccionados de átomo de nitrógeno, átomo de oxígeno y átomo de azufre y es de 3 a 7 miembros; Yd1 es (i) enlace simple o (ii) grupo alquileno C1-6 que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A; o de modo alternativo, tanto Yc como Yd1 pueden ser metino y pueden estar ligados entre sí de forma directa o por medio de grupo alquileno C1-4 forman anillo cicloalquilo C3-7; Yd2 es (i) enlace simple o (ii) grupo alquileno C1-6; Rd1, Rd2, Rd3, Rd4 y Rd5 son un grupo igual o diferente seleccionado de los siguientes (i) a (vii); (i) átomo de hidrógeno, (ii) átomo de halógeno, (ii) grupo alquilo C1-6 que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A, (iv) -ORd10 en donde Rd10 es átomo de hidrógeno o grupo alquilo C1-6 que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A, (v) -COORd11 en donde Rd11 es átomo de hidrógeno o grupo alquilo C1-6, (vi) grupo cicloalquilo C3-7 que puede estar sustituido con 1 a 5 sustituyentes iguales o diferentes seleccionados del grupo A, (vii) grupo ciano, o de modo alternativo, Rd1 y Rd2 o Rd2 y Rd3 se pueden tomar juntos para formar anillo arilo C6-10 fusionado con el anillo benceno al que están todos unidos, en donde el anillo arilo C6-10 puede estar sustituido con 1 a 4 sustituyentes iguales o diferentes seleccionados del grupo A; Re es (i) átomo de hidrógeno o (ii) grupo alquilo C1-3, o de modo alternativo, Re, Rd1 o Re y Rd5 se pueden tomar juntos para formar alquileno C1-4; nc1 es un número entero seleccionado de 0 ó 1 a 4, nc2 es un número entero seleccionado de 0 ó 1 a 3, nd es un número entero seleccionado de 0 ó 1 a 3; grupo A es (a) grupo alquilo C1-6, (b) átomo de halógeno y (c) -ORA1 en donde RA1 es átomo de hidrógeno o grupo alquilo C1-6; o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011100331 | 2011-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086156A1 true AR086156A1 (es) | 2013-11-20 |
Family
ID=47072428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101498A AR086156A1 (es) | 2011-04-28 | 2012-04-27 | Compuesto de amida y su uso medicinal |
Country Status (19)
Country | Link |
---|---|
US (3) | US8604069B2 (es) |
EP (2) | EP2927217B1 (es) |
JP (2) | JP5902029B2 (es) |
KR (1) | KR101964478B1 (es) |
CN (1) | CN103619824B (es) |
AR (1) | AR086156A1 (es) |
AU (1) | AU2012248223B2 (es) |
BR (1) | BR112013027670B1 (es) |
CA (1) | CA2833493C (es) |
CO (1) | CO6801761A2 (es) |
HK (1) | HK1215948A1 (es) |
IL (1) | IL228979A (es) |
MX (1) | MX2013012542A (es) |
PE (1) | PE20141637A1 (es) |
RU (1) | RU2013152788A (es) |
SG (1) | SG194526A1 (es) |
TW (1) | TWI532728B (es) |
WO (1) | WO2012147916A1 (es) |
ZA (1) | ZA201307977B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2013012542A (es) * | 2011-04-28 | 2013-11-20 | Japan Tobacco Inc | Compuestos de amida y aplicacion farmaceutica para el mismo. |
CA2856946C (en) | 2011-12-02 | 2016-08-02 | Phenex Pharmaceuticals Ag | Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmunediseases |
AU2013270036B2 (en) | 2012-05-31 | 2016-12-01 | Phenex Pharmaceuticals Ag | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR(gamma) |
JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
SG11201502935VA (en) | 2012-10-16 | 2015-09-29 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ror-gamma-t |
EP2909192B1 (en) | 2012-10-16 | 2017-05-17 | Janssen Pharmaceutica NV | Methylene linked quinolinyl modulators of ror-gamma-t |
BR112015008515A2 (pt) | 2012-10-16 | 2017-07-04 | Janssen Pharmaceutica Nv | moduladores de ror t de quinolinila ligada à heteroarila |
WO2014065413A1 (ja) * | 2012-10-26 | 2014-05-01 | 日本たばこ産業株式会社 | トリアゾール・イソオキサゾール化合物およびその医薬用途 |
AR093818A1 (es) | 2012-12-06 | 2015-06-24 | Glaxo Group Ltd | Compuesto de 1-(bencil sustituido)piperazina sustituida |
CN104870612B (zh) * | 2012-12-17 | 2017-09-12 | 默克专利股份有限公司 | 液晶显示器和具有垂面配向的液晶介质 |
US10053468B2 (en) | 2013-07-03 | 2018-08-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9745267B2 (en) * | 2013-09-05 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Compounds as modulators of RORC |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
ES2770727T3 (es) | 2013-10-15 | 2020-07-02 | Janssen Pharmaceutica Nv | Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t |
CN105848483A (zh) | 2013-10-15 | 2016-08-10 | 詹森药业有限公司 | RORγt 的喹啉基调节剂 |
CA2927153A1 (en) * | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
SI3102576T1 (sl) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals, Llc | Inhibitorji dihidropirolopiridina ROR-gama |
JPWO2015129853A1 (ja) * | 2014-02-27 | 2017-03-30 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
CA2950211C (en) | 2014-05-28 | 2023-02-07 | Glaxosmithkline Intellectual Property Development Limited | 3-((piperazin-1-yl)methyl)-phenyl amide derivatives and their use as retinoid-related orphan receptor gamma (ror.gamma.) modulators |
CN106660999A (zh) | 2014-05-28 | 2017-05-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 新化合物 |
JP6522665B2 (ja) | 2014-05-28 | 2019-05-29 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 新規化合物 |
WO2016061160A1 (en) | 2014-10-14 | 2016-04-21 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
AU2015362394C1 (en) * | 2014-12-12 | 2021-01-28 | Japan Tobacco Inc. | Dihydropyrimidine-2-one compounds and medicinal uses thereof |
JP6854776B2 (ja) | 2015-01-08 | 2021-04-07 | インぺティス バイオサイエンス リミテッド | 二環式化合物、その組成物および医薬用途 |
WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
MA53943A (fr) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals Llc | Modulateurs de ror-gamma |
TWI691486B (zh) | 2016-01-29 | 2020-04-21 | 日商東麗股份有限公司 | 環狀胺衍生物及其醫藥用途 |
TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
IL298639A (en) | 2017-07-24 | 2023-01-01 | Vitae Pharmaceuticals Llc | Inhibitors of gamma ror |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
CA3071235A1 (en) | 2017-07-27 | 2019-01-31 | Toray Industries, Inc. | Therapeutic agent or preventive agent for alopecia areata |
TW201910312A (zh) * | 2017-07-28 | 2019-03-16 | 日商東麗股份有限公司 | 環狀胺衍生物及其醫藥用途 |
WO2019044940A1 (ja) * | 2017-08-31 | 2019-03-07 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
CN111566098A (zh) | 2018-01-31 | 2020-08-21 | 东丽株式会社 | 环状胺衍生物及其药物用途 |
PE20210550A1 (es) | 2018-02-28 | 2021-03-17 | Japan Tobacco Inc | Compuestos de 4-metildihidropirimidinona y su uso farmaceutico |
WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB768840A (en) * | 1952-11-28 | 1957-02-20 | Cassella Farbwerke Mainkur Ag | Compounds containing a cyclopentyl ring |
US5464860A (en) | 1988-11-30 | 1995-11-07 | Novapharme | N(pyrazol-3-yl) benzamides and pharmaceutical compositions |
FR2639636B1 (fr) | 1988-11-30 | 1994-03-04 | Novapharme | Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant |
US5258397A (en) | 1988-11-30 | 1993-11-02 | Novapharme | 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions |
JPH0789951A (ja) * | 1993-06-03 | 1995-04-04 | Sterling Winthrop Inc | インターロイキン−1β転換酵素阻害剤 |
JPH09278741A (ja) * | 1996-04-10 | 1997-10-28 | Tanabe Seiyaku Co Ltd | フェノール誘導体 |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
US6100260A (en) * | 1997-04-21 | 2000-08-08 | Sumitomo Pharmaceutical Company, Limited | Isoxazole derivatives |
JP3237608B2 (ja) * | 1997-04-21 | 2001-12-10 | 住友製薬株式会社 | イソキサゾール誘導体 |
AU2160899A (en) | 1997-12-11 | 1999-06-28 | Janssen Pharmaceutica N.V. | Retinoic acid mimetic anilides |
WO2003057215A1 (fr) | 2001-12-28 | 2003-07-17 | Takeda Chemical Industries, Ltd. | Accelerateur de production/secretion de facteur neurotrophique |
CA2545711A1 (en) | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Urea derivatives as kinase modulators |
MX2007003161A (es) * | 2004-09-16 | 2007-05-16 | Astellas Pharma Inc | Derivado de triazol o una sal del mismo. |
TWI435875B (zh) | 2008-07-08 | 2014-05-01 | Daiichi Sankyo Co Ltd | 含氮芳香族雜環化合物 |
EP2181710A1 (en) * | 2008-10-28 | 2010-05-05 | Phenex Pharmaceuticals AG | Ligands for modulation of orphan receptor-gamma (NR1F3) activity |
JP2012510979A (ja) | 2008-12-08 | 2012-05-17 | ユーロスクリーン・ソシエテ・アノニム | 化合物、薬学的組成物および代謝障害の治療において使用するための方法 |
WO2010096170A2 (en) * | 2009-02-19 | 2010-08-26 | President And Fellows Of Harvard College | Inhibition of trna synthetases and therapeutic applications thereof |
MX2013012542A (es) * | 2011-04-28 | 2013-11-20 | Japan Tobacco Inc | Compuestos de amida y aplicacion farmaceutica para el mismo. |
-
2012
- 2012-04-27 MX MX2013012542A patent/MX2013012542A/es unknown
- 2012-04-27 EP EP14199821.1A patent/EP2927217B1/en active Active
- 2012-04-27 CA CA2833493A patent/CA2833493C/en active Active
- 2012-04-27 PE PE2013002400A patent/PE20141637A1/es active IP Right Grant
- 2012-04-27 JP JP2012102317A patent/JP5902029B2/ja active Active
- 2012-04-27 BR BR112013027670-3A patent/BR112013027670B1/pt active IP Right Grant
- 2012-04-27 SG SG2013077490A patent/SG194526A1/en unknown
- 2012-04-27 WO PCT/JP2012/061352 patent/WO2012147916A1/ja active Application Filing
- 2012-04-27 EP EP12776819.0A patent/EP2719690A4/en not_active Withdrawn
- 2012-04-27 RU RU2013152788/04A patent/RU2013152788A/ru not_active Application Discontinuation
- 2012-04-27 AR ARP120101498A patent/AR086156A1/es not_active Application Discontinuation
- 2012-04-27 AU AU2012248223A patent/AU2012248223B2/en active Active
- 2012-04-27 US US13/457,844 patent/US8604069B2/en active Active
- 2012-04-27 TW TW101115108A patent/TWI532728B/zh active
- 2012-04-27 KR KR1020137028186A patent/KR101964478B1/ko active IP Right Grant
- 2012-04-27 CN CN201280032213.1A patent/CN103619824B/zh active Active
-
2013
- 2013-10-16 ZA ZA2013/07977A patent/ZA201307977B/en unknown
- 2013-10-21 IL IL228979A patent/IL228979A/en active IP Right Grant
- 2013-10-25 CO CO13253890A patent/CO6801761A2/es active IP Right Grant
- 2013-10-30 US US14/067,175 patent/US20140296306A1/en not_active Abandoned
-
2015
- 2015-12-28 US US14/981,108 patent/US20160346256A1/en not_active Abandoned
-
2016
- 2016-03-09 JP JP2016046017A patent/JP2016147880A/ja active Pending
- 2016-04-06 HK HK16103899.8A patent/HK1215948A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR086156A1 (es) | Compuesto de amida y su uso medicinal | |
AR064454A1 (es) | Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
AR080057A1 (es) | Piridinas disustituidas como anticancerigenos | |
AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
CO6761320A2 (es) | Derivados de piperidina puenteada | |
AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
AR084905A1 (es) | Derivados de 2,3-dihidro-furo[2,3-c]piridina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por la activacion del receptor gpr119 acoplado a proteinas g | |
AR095609A1 (es) | Compuestos de pirrolopiridina | |
AR085586A1 (es) | Derivados de acido 3-fenilpropionico ramificados y su uso como activador de sgc | |
AR092838A1 (es) | COMPUESTOS TIPO PIRROLO-PIRROLIDINONA COMO INHIBIDORES DE LA INTERACCION ENTRE p53 Y MDM2 Y/O MDM4 | |
AR086319A1 (es) | Compuestos heterociclicos fusionados como moduladores de canal ionico | |
AR073406A1 (es) | Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
AR081315A1 (es) | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t | |
AR087487A1 (es) | Compuestos heterociclicos derivados de pirimidina como inhibidores de las kinasas activadas janus (jak) | |
AR078463A1 (es) | Composicion y metodo para controlar plagas de artropodos | |
AR087311A1 (es) | Quinolinas sustituidas y su uso como medicamentos | |
AR092288A1 (es) | Ligandos del receptor ep1 | |
AR087052A1 (es) | Derivados de amina ciclica como antagonistas del receptor ep4 | |
AR083579A1 (es) | Inhibidor de cetp de oxazodilinona sustituida con amina ciclica | |
AR085990A1 (es) | Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen | |
AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
ES2577382T3 (es) | Nuevos derivados de tienopirimidina, procedimientos para su preparación, y sus usos terapéuticos | |
AR077510A1 (es) | Derivados de dihidroindolonas, su procedimiento de preparacion y las com-posiciones farmaceuticas que los contienen | |
AR066604A1 (es) | Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente. | |
AR075920A1 (es) | Derivados de nicotinamida su preparacion y su aplicacion en terapeutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |